Routes of
administration Intravenous Bioavailability N/A Molar mass 695.93 g/mol Pubchem 9810246 | ATC code V10BX02 (WHO) PubChem CID 9810246 Route Intravenous therapy ChEMBL ID 1201796 | |
 | ||
Pregnancy
category US: D (Evidence of risk) Legal status In general: ℞ (Prescription only) | ||
Samarium (153Sm) lexidronam (chemical name Samarium-153-ethylene diamine tetramethylene phosphonate, abbreviated Samarium-153 EDTMP, trade name Quadramet) is a chelated complex of a radioisotope of the element samarium with EDTMP. It is used to treat pain when cancer has spread to the bone.
Contents
It is injected into a vein and distributed throughout the body, where it is preferentially absorbed in areas where cancer has invaded the bone. The radioisotope 153Sm, with a half-life of 46.3 hours, decays by emitting beta particles (electrons), which kill the nearby cells. Pain begins to improve in the first week for most people and the effects can last several months. It is commonly used in lung cancer, prostate cancer, breast cancer, and osteosarcoma.
Side effects
Side effects include the following:
Supply and administration
Quadramet is supplied as a frozen solution for intravenous use with an activity of 50±5 mCi/mL. Due to the short half-life of the radioisotope, the drug expires 56 hours after the noted calibration time. Currently supported by Lantheus Medical Imaging.